The following is a summary of “Cutaneous manifestations of Fabry disease: A systematic review,” published in the March 2025 ...

"Health being a state subject, the primary responsibility of providing healthcare services is that of state governments.

Around 1,000 patients with rare diseases are registered with Centres of Excellence in India. The government allocated ...

Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...

Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while ...

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Dr Anup Rawool, Consultant in Clinical and Cancer Genetics at Sahyadri Hospitals, Pune, discusses innovative therapies and ...

Learn more about whether Alvotech or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.